Novel insulin products: Why would patients, professionals and industry want them?

British Journal of Diabetes

View Publication Info
 
 
Field Value
 
Title Novel insulin products: Why would patients, professionals and industry want them?
 
Creator Stokes, Vicky; Oxford Centre for Diabetes, Endocrinology and Metabolism, Churchill Hospital, Oxford, UK
Rozario, Kavitha Sebastian; Paediatric Endocrinology, John Radcliffe Hospital, Oxford, UK.
George, Jyothis; Boehringer Ingelheim Ltd, Bracknell, UK; Warwick Medical School, University of Warwick, Coventry, UK; Diabetes and Endocrinology, Royal Berkshire Hospital, Reading, UK
 
Subject
insulin, biosimilar, glycaemic control
 
Description Multiple innovations over a century have improved the safety, tolerability and clinical acceptability of insulin. From a therapeutic option that required multiple injections a day, often with a poor predictability, insulin has evolved into a treatment approach that an empowered patient can self-administer safely. It is the most potent glucose-lowering therapy and has hence seen widespread clinical adoption in the last two decades in the treatment of type 2 diabetes.At the same time, the unit-costs of insulin have not declined as is often the case with long established therapies. We review the history of insulin as a drug, charting its course from early experiments to modern insulin therapies. We consider the need (or lack thereof) for novel insulin from the perspectives of patients, healthcare professionals and healthcare payers. Whilst there are many valid arguments to support the development of novel insulins, healthcare systems and payers will require a clear demonstration of value for any novel insulin product. If a premium price (i.e. a higher price than comparable products) is demanded by manufacturers, healthcare payers would rightly seek evidence of added value – this could involve clear markers of increased safety and efficacy and/or the offsetting of other diabetes-related costs.
 
Publisher ABCD (Diabetes Care) Ltd
 
Contributor
 
Date 2016-12-20
 
Type info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion

 
Format text/html
application/pdf
 
Identifier http://www.bjd-abcd.com/index.php/bjd/article/view/206
10.15277/bjd.2016.110
 
Source British Journal of Diabetes; Vol 16, No 4 (2016); 198-201
2397-6241
2397-6233
 
Language eng
 
Relation http://www.bjd-abcd.com/index.php/bjd/article/view/206/349
http://www.bjd-abcd.com/index.php/bjd/article/view/206/350
 
Coverage


 
Rights Copyright (c) 2016 British Journal of Diabetes
 

Contact Us

The PKP Index is an initiative of the Public Knowledge Project.

For PKP Publishing Services please use the PKP|PS contact form.

For support with PKP software we encourage users to consult our wiki for documentation and search our support forums.

For any other correspondence feel free to contact us using the PKP contact form.

Find Us

Twitter

Copyright © 2015-2016 Simon Fraser University Library